Pegfilgrastim Biosimilar Approved in Europe

November 27, 2018 – The European Commission has granted approval to the biosimilar LA-EP2006, a biosimilar for pegfilgrastim, as a treatment to reduce the duration of neutropenia and incidence of febrile neutropenia that is associated with anticancer chemotherapy, according to Sandoz, the developer of the agent. LA-EP2006 is now authorized for use in the same proposed indications as reference pegfilgrastim, which is to prevent febrile neutropenia in patients … (leggi tutto)